CSIMarket
 
Hepion Pharmaceuticals inc   (HEPA)
Other Ticker:  
 
 
Price: $2.2600 $0.22 10.784%
Day's High: $2.36 Week Perf: 0.89 %
Day's Low: $ 1.96 30 Day Perf: 14.14 %
Volume (M): 41 52 Wk High: $ 20.66
Volume (M$): $ 92 52 Wk Avg: $4.92
Open: $2.20 52 Wk Low: $0.47



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -45
 Cash Flow (TTM) (Millions $) -40
 Capital Exp. (TTM) (Millions $) 0

Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals Inc. is a biopharmaceutical company that is focused on the development of innovative therapies for liver diseases. The company's primary area of expertise is in the research and development of drugs targeting fibrosis, a common complication of chronic liver disease. Hepion Pharmaceuticals aims to address the unmet medical needs of patients suffering from liver-related conditions by discovering and advancing novel therapeutic candidates. Their research efforts are primarily centered on developing drugs that can reduce fibrosis and improve liver function. The company is committed to bringing new treatment options to patients and improving their quality of life.


   Company Address: 399 Thornall Street Edison 8837 NJ
   Company Phone Number: 902-4000   Stock Exchange / Ticker: NASDAQ HEPA
   HEPA is expected to report next financial results on April 09, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc Faces Mounting Expenses During Third Quarter of 2023 Earnings Season



As the earnings cycle for the fiscal period from July to September 2023 progresses, numerous companies across various industries have been disclosing their financial numbers. One industry that has seen significant activity in this regard is the Major Pharmaceutical Preparations industry, with Hepion Pharmaceuticals Inc (HEPA) being one of the companies in focus. In its recent announcement, HEPA revealed an operating loss of $-10.664565 million for the third quarter of 2023. While investors eagerly anticipate new revenue streams, they remain less concerned about the company's recent operational performance. This article will examine the implications of HEPA's earnings within the context of its financial results.
Financial Performance of Hepion Pharmaceuticals Inc
HEPA's financial results for the third quarter of 2023 revealed an operating loss of $-10.664565 million. This figure represents a significant increase from the operating loss of $-8.548 million reported in the same quarter of the previous year, highlighting a growing shortfall in revenue. The company's shareholders, however, are more interested in the arrival of new revenue streams rather than dwelling on the recent operational performance.

Product Service News

Hepion Pharmaceuticals to Unveil Groundbreaking Efficacy Data for Rencofilstat at AASLD 2023, Revolutionizing NASH Treatment

Published Fri, Nov 10 2023 1:50 PM UTC



Hepion Pharmaceuticals, a leading biopharmaceutical company focused on the development of innovative therapeutics for liver diseases, has recently announced the scheduling of a conference call to review additional efficacy data from its Phase 2 ALTITUDE-NASH liver function trial of Rencofilstat. The highly anticipated data release is set to follow a late-breaker po...

Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc Shows Significant Progress in Reducing Operating Shortfall to $-14.16563 million in Q2 2023

As the earnings season for the April to June 30, 2023 period continues, several corporations in the Major Pharmaceutical Preparations industry have disclosed their results. One such company is Hepion Pharmaceuticals Inc (HEPA), which has recently reported an operating shortfall of $-14.16563 million for the period. This marks a significant improvement compared to the second quarter of 2022, where the operating shortfall stood at $-19.998121 million.
The decrease in operating shortfall can be seen as a positive signal for the condition of the company. As a growing business, it is crucial for companies like Hepion Pharmaceuticals to efficiently execute their business strategy in order to reach the next stage of growth. Despite still developing their strategy, Hepion Pharmaceuticals managed to reduce their losses in the financial period ending June 30, 2023, to $-14.080 million. This is a substantial reduction from the $-19.911 million reported in the second quarter of 2022.

Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc Faces Alarming Operating Losses and Revenue Questions in First Quarter of 2023 Earnings Season

The Major Pharmaceutical Preparations sector advisors have been closely analyzing the first quarter of 2023 performance, and have noted that Hepion Pharmaceuticals Inc has reported an operating loss of $-13.209165 million. This is a significant decrease from the same period in 2022, where the operating loss was reported at $-7.252468 million.
What is more concerning, however, is that Hepion Pharmaceuticals Inc has not cited any revenue for the respective January to March 31 2023 financial reporting period. This is generating speculation among market observers who are questioning if the company will start generating revenue again. Notably, the company recorded a shortfall of $-13.260 million, which is an increase from -$6.930 million in the first quarter of 2022.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com